Director at Sana Biotechnology (SANA) granted 7,763 fully vested RSUs

Rhea-AI Filing Summary

Bishop Hans Edgar reported acquisition or exercise transactions in this Form 4 filing.

Sana Biotechnology, Inc. director Hans Edgar Bishop received an award of 7,763 shares of Common Stock on April 6, 2026. The filing notes these shares consist of fully vested restricted stock units granted at no cash cost per share, as part of his equity compensation.

After this grant, Bishop directly holds a total of 5,848,503 shares of Common Stock. Because the shares were awarded rather than bought in the open market, this transaction is primarily a routine compensation event, not a market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bishop Hans Edgar

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,763	$0.00	--

Holdings After Transaction: Common Stock — 5,848,503 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU shares granted: 7,763 shares Grant price per share: $0.00 per share Total shares after transaction: 5,848,503 shares

3 metrics

RSU shares granted 7,763 shares Fully vested restricted stock units granted on April 6, 2026

Grant price per share $0.00 per share Equity award with no cash paid by insider

Total shares after transaction 5,848,503 shares Hans Edgar Bishop direct Common Stock holdings after award

Key Terms

restricted stock units, Common Stock, Form 4

3 terms

restricted stock units financial

"Consists of fully vested restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Common Stock financial

"security_title: "Common Stock" in the transaction details"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bishop Hans Edgar

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/06/2026		A		7,763(1)	A	$0.00	5,848,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of fully vested restricted stock units.

Remarks:

	/s/ Aaron M. Grossman, Attorney-in-Fact for Hans Edgar Bishop	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Sana Biotechnology (SANA) report for Hans Edgar Bishop?

Sana Biotechnology reported that director Hans Edgar Bishop received 7,763 shares of Common Stock as a fully vested restricted stock unit award. The grant carried a price of $0.00 per share, reflecting equity compensation rather than a cash purchase in the market.

How many Sana Biotechnology (SANA) shares does Hans Edgar Bishop hold after this Form 4?

After the reported award, Hans Edgar Bishop directly holds 5,848,503 shares of Sana Biotechnology Common Stock. This total includes the 7,763 fully vested restricted stock units granted on April 6, 2026, as disclosed in the Form 4 insider transaction report.

Was the Sana Biotechnology (SANA) transaction a stock purchase or a compensation grant?

The transaction was a compensation grant, not a market purchase. Hans Edgar Bishop received 7,763 fully vested restricted stock units at $0.00 per share, indicating an equity award rather than buying shares on the open market for cash consideration.

What type of security was involved in the Sana Biotechnology (SANA) Form 4 filing?

The Form 4 filing involved Sana Biotechnology Common Stock delivered through fully vested restricted stock units. These RSUs converted into 7,763 shares at no cash cost to director Hans Edgar Bishop, increasing his direct ownership position in the company’s common equity.

Does the Sana Biotechnology (SANA) Form 4 show any insider selling activity?

The Form 4 does not show any insider selling activity. It reports only an acquisition: 7,763 shares of Common Stock awarded as fully vested restricted stock units to director Hans Edgar Bishop, increasing his holdings to 5,848,503 shares following the transaction.